Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Äèñêóññèîííûå ôîðóìû > Ðàçíîå

Ðàçíîå Ëþáûå ñîîáùåíèÿ íà ìåäèöèíñêèå òåìû, ïî êîòîðûì íåò îòäåëüíûõ ôîðóìîâ. Ôîðóì: ×àñòíàÿ ïðàêòèêà.

Çàêðûòàÿ òåìà
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1471  
Ñòàðûé 20.10.2003, 17:46
Àâàòàð äëÿ yananshs
yananshs yananshs âíå ôîðóìà Ïîë æåíñêèé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.02.2003
Ãîðîä: NY
Ñîîáùåíèé: 9,664
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 56 ðàç(à) çà 51 ñîîáùåíèé
yananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âû çíàåòå, Âëàäèìèð ßêîâëåâè÷, èíîãäà Âû íàïîìèíàåòå äîêòîðà Ðàâèíî èç "Ãîëîâû ïðîôåññîðà Äîóýëÿ", ïûòàþùåãîñÿ ñâåñòè ñâîèõ ñîáåñåäíèêîâ ñ óìà èåçóèòñêèìè áåñåäàìè, äîêàçûâàÿ èì, ÷òî ÷åðíîå ýòî áåëîå, à áåëîå, ýòî ÷åðíîå. Âûäåðæèâàþò ñàìûå êðåïêèå. Òå, êòî ÷óâñòâóåò, ÷òî íåðâíàÿ ñèñòåìà íå âûäåðæèâàþò, ïåðåñòàþò ÷èòàòü Âàøè ïîñòû.
  #1472  
Ñòàðûé 20.10.2003, 18:40
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Âîò è ëàäóøêè, ßíà!
Äëÿ íàøåãî ñ Âàìè äóøåâíîãî ñïîêîéñòâèÿ áóäåò ðàñïðåêðàñíî, åñëè Âû ìîè ïîñòû âîîáùå ÷èòàòü ïåðåñòàíåòå. ß âåäü ê Âàì â ãîñòè íà ôîðóìå íå ïðèõîäèë è ëè÷íî Âàì èëè Åâãåíèé Åâãåíüåâè÷ó, ïîâåðòè, íè÷åãî äîêàçûâàòü íå ñîáèðàëñÿ. Ïîíà÷àëó, íà Âàøè íàñòàâëåíèÿ â îáëàñòÿõ, ñ êîòîðûìè ñâÿçàí è ðàçáèðàþñü óæ íå õóæå, ïàðó ðàç íàìåêíóë, ÷òî, âîçìîæíî, áîëåå öåëåñîîáðàçíî è ïîçíàâàòåëüíî óñëûøàòü îò Âàñ î ðàíäîìèçèðîâàííûõ èñïûòàíèÿõ ñ ÐÉ èëè îá îòäàëåííûõ (÷åðåç ãîäà) ïîñëåäñòâèÿõ, ðàç âñå áîëåå ìîëîäûì ïàöèåíòàì ïðåäëàãàåòñÿ òàêîå ëå÷åíèå. Íî Âàñ áîëüøå âîëíîâàëè âîïðîñû, ñâÿçàííûå ñ ìîåé äåÿòåëüíîñòüþ. È ÿ áûë âûíóæäåí îòâå÷àòü.
  #1473  
Ñòàðûé 20.10.2003, 18:58
E.E. Studentsov E.E. Studentsov âíå ôîðóìà
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 29.06.2003
Ãîðîä: New York, USA
Ñîîáùåíèé: 834
Ñêàçàë(à) ñïàñèáî: 2
Ïîáëàãîäàðèëè 6 ðàç(à) çà 4 ñîîáùåíèé
E.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Âëàäèìèð ßêîâëåâè÷,

Âû ïèøeòå:

From the 12th December 2002 issue of Journal of the American Medical Association, in a review with James Spencer Malpas, M.D., D.Phil. St. Bartholomew's Hospital London, United Kingdom:
"a recent randomized trial of treatment for stage one multiple myeloma by Riccardi and colleagues (British Journal of Cancer 2000;82:1254-60) showed no advantage of conventional chemotherapy over no treatment." [êîíåö öèòàòû] Îé, íå âïå÷àòëÿåò.

Ïîÿñíèòå:
1. Î êàêîì íîìåðå JAMA èä¸ò ðå÷ü? ò.ê. íîìåðà îò 12 äåêàáðÿ íå ñóùåñòâóåò.
2. Î êàêîì äîêòîðå èä¸ò ðå÷ü? Äîêòîð James Spenser Malpas îïóáëèêîâàë ïîñëåäíþþ ðàáîòó â JAMA â 1981 ãîäó.
Âîò åãî ðàáîòû:
R. M. Chapman, S. B. Sutcliffe, and J. S. Malpas
Male gonadal dysfunction in Hodgkin's disease. A prospective study
JAMA 1981 245: 1323-1328.

R. M. Chapman, S. B. Sutcliffe, and J. S. Malpas
Cytotoxic-induced ovarian failure in Hodgkin's disease. II. Effects on sexual function
JAMA 1979 242: 1882-1884.

R. M. Chapman, S. B. Sutcliffe, and J. S. Malpas
Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function
JAMA 1979 242: 1877-1881.


3. Îçíàêîìèëèñü ëè Âû ñ ïîëíûì òåêñòîì ðàáîòû Ä-ðà Riccardi äëÿ å¸ îáñóæäåíèÿ?

4. Ãîòîâû ëè Âû ê ñåðü¸çíîìó ðàçáîðó òàêòèêè âåäåíèÿ áîëüíûõ ñ "multiple myeloma" ñ ïðîôåññèîíàëàìè?

5. Åñëè Äà, òî çà÷åì ýòî Âàì?

6. Âûáðàííûé Âàì èñòî÷íèê öèòèðîâàíèÿ ðàáîò ä-ðà Malpas [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
íå ñîâñåì ïîäõîäèò äëÿ Ðóññêîãî ÌÅÄÈÖÈÍÑÊÎÃÎ Ñåðâåðà. Ò.ê. èìåþ ïîäîçðåíèå, ÷òî ýòè ðåáÿòà êàê ðàç è åñòü ñàìûå íàñòîÿùèå æóëèêè. Îò êîíòàêòîâ ñ êîèìè Âû òàê îòêðåùèâàåòåñü.


Ñ óâàæåíèåì,

Å.Å Ñòóäåíöîâ
  #1474  
Ñòàðûé 20.10.2003, 20:54
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Óâàæàåìûé Åâãåíèé Åâãåíüåâè÷!
Âû ñîâåðøåííî ïðàâû, ññûëêó ÿ ïîçàèìñòâîâàë èç Alternative Cancer Treatments Cantron and Protocel ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]).
Ïîñëå Âàøåãî çàìå÷àíèÿ ðåøèë ïðîâåðèòü, èìååò ìåñòî êàêàÿ-íèáóäü òåõíè÷åñêàÿ îïèñêà èëè ïîäîáíîé ïóáëèêàöèè â British Journal of Cancer 2000;82:1254-60 âîîáùå íå ñóùåñòâóåò?
 ïîñëåäíåì ñëó÷àå, åñòåñòâåííî, ïðèíåñ áû èçâèíåíèÿ, ÷òî äîâåðèëñÿ íåäîñòîâåðíîìó èñòî÷íèêó.
Âîò, ÷òî äîïîëíèòåëüíî ÿ «íàðûë»:

N Engl J Med 2002; 347:1986, Dec 12, 2002

Living Proof: A Medical Mutiny
By Michael Gearin-Tosh. 334 pp. New York, Scribner, 2002. $25. ISBN 0-7432-2517-1.
This book is an autobiographical account by a classicist and fellow of St. Catherine's College, Oxford, who received a diagnosis of multiple myeloma. He refused conventional medical treatment yet has survived for more than eight years. His case was reviewed by leading oncologists and physicians in Britain and the United States, and it was confirmed that he had stage 1 multiple myeloma. Stage 1 multiple myeloma occupies a borderland between the relatively benign form of the disease, so-called smoldering myeloma, and the aggressive classic form of the disease. It is not uncommon for an oncologist with a practice in myeloma to see a patient with stage 1 myeloma who survives for many years. The treatment offered by conventional medicine to Gearin-Tosh was intensive chemotherapy, with the hope of eradicating the disease and prolonging his life. Another option was simply to keep his condition under careful surveillance, but this is not mentioned in his account of his consultations. After much thought he refused a conventional approach, and with the help of close friends, he explored various alternative, or complementary, therapies.
Why did this intelligent, erudite, and by his own admission, obstreperous man write this book? Journalists seized on it and used it to vilify orthodox medical practice and doctors in general. This was grossly unfair, for Gearin-Tosh does no such thing in his book. He is remarkably even-handed and very perceptive, seeing both the good and bad in both orthodox and alternative approaches. He describes vividly the turmoil and terror at first hearing the diagnosis, and as he looked at the depressing survival curves in the textbooks, one can well imagine his distress at the "terrifying reality." He deals frankly with the intimacies of the medical consultation, which is one of the book's most valuable contributions. Robert Burns said, "O wad some Pow'r the giftie gie us/To see oursels as others see us," and for those of us in the healing professions, Gearin-Tosh shines a bright light on our deficiencies.
There is lively writing about his life, his friends, his love of the stage and literature, and the comfort and support he got from his books. You know that it would have been a privilege to have had him as a tutor. There are interesting reflections on various characters at the university and on that most convoluted system of education, the Oxford collegiate system, which nevertheless supported him in his hour of need.
So Living Proof of what? Having survived, Gearin-Tosh feels he has the right to draw lessons from his experience. He advocates taking time to consider the opinions offered, and certainly nobody could disagree with that. It would have been right to emphasize that this should be done only after a clinical assessment to rule out such devastating complications as incipient paralysis from spinal cord compression and kidney failure, both of which can develop quickly in classic multiple myeloma. I am sure Gearin-Tosh did not wish to give bad advice to others who have received a diagnosis of multiple myeloma, but the publication of the book and its misinterpretation by the press did prompt the United Kingdom branch of the International Myeloma Foundation, an excellent patient-support organization, to respond with a front-page editorial because so many patients and their families had been upset.
Gearin-Tosh's second assertion is that one needs "proof against proof." He believes that patients are very vulnerable and that with the use of statistics, they can be propelled in a direction in which they do not wish to go. He found the evidence in favor of conventional treatment unconvincing and opted for such alternative therapies as Gerson therapy with its strict diet, vitamins, and enemas. High-dose vitamin C and high-dose vitamin D, both contraindicated in the orthodox treatment of multiple myeloma, were later added to the regimen. What is evident is that this was the right therapy for him. He chose it, he has been able to control it, and although it seems far worse than conventional chemotherapy, he has been able to tolerate it and is alive. The irony of the whole situation is that a recent randomized trial of treatment for stage 1 multiple myeloma by Riccardi and colleagues (British Journal of Cancer 2000;82:1254-60) showed no advantage of conventional chemotherapy over no treatment. Would Gearin-Tosh have accepted that proof? I wonder.

James Spencer Malpas , M.D., D.Phil.
St. Bartholomew's Hospital
London EC1A 7BE, United Kingdom

Åñòü íåîáõîäèìîñòü â äàëüíåéøèõ ïîèñêàõ, â ÷àñòíîñòè, ïåðâîèñòî÷íèêà â British Journal of Cancer? Èëè îñòàíîâèìñÿ íà ýòîé èíôîðìàöèè?
Âàøè «ïîäîçðåíèÿ, ÷òî ýòè ðåáÿòà êàê ðàç è åñòü ñàìûå íàñòîÿùèå æóëèêè» ðàçðåøèòå íå êîììåíòèðîâàòü, òàê êàê èìåþ äîâîëüíî ñìóòíîå ïðåäñòàâëåíèÿ îá ýòèõ «ðåáÿòàõ», êàê è îá èõ ðàáîòàõ, èññëåäîâàíèÿõ. È òàêèå îáâèíåíèÿ äàæå â ñóäå, íå âûñëóøàâ îáâèíÿåìîãî, àäâîêàòà óòâåðæäàòü íå ïðèíÿòî. À ó ìåíÿ ê ñîæàëåíèþ (èëè ê ñ÷àñòüþ) íåò òàêèõ ñïîñîáíîñòåé ê îöåíêàì, êàê ó Âàñ èëè ä-ðà Æèâîâà.
  #1475  
Ñòàðûé 20.10.2003, 22:00
Àâàòàð äëÿ yananshs
yananshs yananshs âíå ôîðóìà Ïîë æåíñêèé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.02.2003
Ãîðîä: NY
Ñîîáùåíèé: 9,664
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 56 ðàç(à) çà 51 ñîîáùåíèé
yananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Âëàäèìèð ßêîâëåâè÷!
Åñëè Âàñ äåéñòâèòåëüíî çàèíòåðåñîâàëà òèðîèäîëîãèÿ, ìîæíî íà÷àòü ñ ðàáîò M.Schlumberger, E. Mazzaferri, J.E.Freitas. Èì ïðèíàäëåæàò òàêæå áîëüøèå îáçîðíûå ñòàòüè, â êîòîðûõ åñòü ññûëêè íà òå èññëåäîâàíèÿ, êîòîðûå Âàñ çàèíòåðåñîâàëè. Êðîìå òîãî, Âàì, âîçìîæíî, áóäóò èíòåðåñíû ñëåäóþùèå ðàáîòû:

Ward L, Huot C, Lambert R, Deal C, Collu R, Van Vliet G.
Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine.Clin Invest Med. 1999 Aug;22(4):132-9.

Ljunggren JG, Torring O, Wallin G, Taube A, Tallstedt L, Hamberger B, Lundell G.
Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study.Thyroid. 1998 Aug;8(8):653-9.

Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M, Hamberger B.
Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group.J Clin Endocrinol Metab. 1996 Aug;81(8):2986-93.

Gittoes NJ, Franklyn JA.
Hyperthyroidism. Current treatment guidelines.Drugs. 1998 Apr;55(4):543-53. Review.

Waldhausen JH.
Controversies related to the medical and surgical management of hyperthyroidism in children.Semin Pediatr Surg. 1997 Aug;6(3):121-7. Review.

Robbins J, Schneider AB.
Thyroid cancer following exposure to radioactive iodine.Rev Endocr Metab Disord. 2000 Apr;1(3):197-203. Review.

Malone JF.
The radiation biology of the thyroid.Curr Top Radiat Res Q. 1975 Oct;10(4):263-368. Review.

Ïðèÿòíîãî ÷òåíèÿ.
  #1476  
Ñòàðûé 20.10.2003, 22:23
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Ñïàñèáî.
  #1477  
Ñòàðûé 20.10.2003, 22:48
E.E. Studentsov E.E. Studentsov âíå ôîðóìà
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 29.06.2003
Ãîðîä: New York, USA
Ñîîáùåíèé: 834
Ñêàçàë(à) ñïàñèáî: 2
Ïîáëàãîäàðèëè 6 ðàç(à) çà 4 ñîîáùåíèé
E.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Âëàäèìèð ßêîâëåâè÷!

×ðåçâû÷àéíî ðàä, ÷òî íàêîíåö-òî ñóìåë óáåäèòü Âàñ â íåïðàâîìåðíîñòè ñóæäåíèé ïðåäñòàâèòåëåé àëüòåðíàòèâíîé ìåäèöèíû. Êàê ðåçóëüòàò - Âàøè "ðàñêîïêè" íàêîíåö-òî óâåí÷àëèñü óñïåõoì, è Âû ïðèâåëè ïðåêðàñíóþ àííoòàöèþ äîêòîðà Malpas î êíèãå Gearin-Tosh "Living Proof", íàïå÷àòàííóþ â îäíîì èç ñàìûõ ïðåñòèæíûõ ìåäèöèíñêèõ æóðíàëoâ. Ïîçäðàâëÿþ Âàñ è äîáðî ïîæàëîâàòü â íàøè ðÿäû. Ïðî÷èòàâ ýòó àííoòàöèþ, Âû, áåçóñëîâíî, íå ñìîãëè íå çàìåòèòèòü, ÷òî äëèòåëüíîå âðåìÿ çàáëóæäàëèñü, âñëåäñòâèå îòñóòñòâèÿ äîñòîâåðíîé èíôîðìàöèè âî ìíîãèõ èñòî÷íèêàõ, ïðîïàãàíäèðóþùèõ àëüòåðíàòèâíûå ìåòîäû. Ïîñëåäíÿÿ èíòåðíåò-ñòðàíè÷êà - íàãëÿäíûé òîìó ïðèìåð: æóëèêè âûõâàòèëè ýïèçîä âûñêàçàâàíèÿ èçâåñòíîãî è óâàæàåìîãî äîêòîðà è ëîâêî èñïîëüçîâàëè åãî â ñâîèõ öåëÿõ. Ïðè ýòîì îíè èñêóñíî çàìåëè ñëåäû, èçìåíèâ èñïîëüçóåìûé èñòî÷íèê, ÷òîáû íàèâíûé ÷èòàòåëü(ïîòåíöèàëüíûé êëèåíò) íå ñìîã íàéòè îðèãèíàë è ñôîðìèðîâàòü îáúåêòèâíîå ìíåíèå. Íî íàñ ñ Bàìè íå ïðîâåäåøü!!! âåäü ìû óìååì ïîëüçîâàòüñÿ ìåäèöèíñêèìè ïîèñêîâûìè ñèñòåìàìè è ñóìåëè âûâåñòè ýòèõ øàðëàòàíîâ íà ÷èñòóþ âîäó. ß ðàä, óâàæàåìûé Âëàäèìèð ßêîâëåâè÷, ÷òî ýòî ñäåëàëè èìåííî Âû. È òåïåðü âñå íàêîíåö-òî ñîãëàñÿòñÿ ñ Âàìè è âïåðâûå çà äîëãèå ãîäû ðàçäåëÿò Âàøå ìíåíèå. Òàê äåðæàòü, Âëàäèìèð ßêîâëåâè÷! ß èñêðåííå ðàäóþcü âìåñòå ñ Âàìè.

Ñ ãëóáîêèì óâàæåíèåì,

Å.Å. Ñòóäåíöîâ
  #1478  
Ñòàðûé 21.10.2003, 00:18
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Óâàæàåìûé Åâãåíèé Åâãåíüåâè÷!
Ðàäîñòü, êîíå÷íî, ïðåêðàñíîå ÷óâñòâî è â ýòîì ïëàíå ìîãó òîëüêî Âàì ïîçàâèäîâàòü. Âîò åñëè áû è ÿ åù¸ äî êîíöà ýòó ðàäîñòü ïîíÿë. Âû ïèøèòå, ÷òî «æóëèêè âûõâàòèëè ýïèçîä âûñêàçûâàíèÿ èçâåñòíîãî è óâàæàåìîãî äîêòîðà è ëîâêî èñïîëüçîâàëè åãî â ñâîèõ öåëÿõ. Ïðè ýòîì îíè èñêóñíî çàìåëè ñëåäû, èçìåíèâ èñïîëüçóåìûé èñòî÷íèê, ÷òîáû íàèâíûé ÷èòàòåëü (ïîòåíöèàëüíûé êëèåíò) íå ñìîã íàéòè îðèãèíàë è ñôîðìèðîâàòü îáúåêòèâíîå ìíåíèå». Íî èçâèíèòå, åäèíñòâåííàÿ òåõíè÷åñêàÿ îøèáêà, ÷òî «æóëèêè» îøèáëèñü ñ íàçâàíèåì æóðíàëà, íî ïðè ýòîì îíè íè éîòó íå èçìåíèëè íè ñàìó ôðàçó èçâåñòíîãî è óâàæàåìîãî äîêòîðà, íè ïåðâîèñòî÷íèê, ãäå ýòî èññëåäîâàíèå áûëî îïóáëèêîâàíî. È ïîòîì, Åâãåíèé Åâãåíüåâè÷, ðàçâå J. S. Malpas âûñêàçûâàåòñÿ î ðàññìàòðèâàåìûõ òåðàïèÿõ, êàê áåçóñëîâíî øàðëàòàíñêèõ? Ïðî÷òèòå, ïîæàëóéñòà, ýòî ïðåäèñëîâèå åù¸ ðàç. He is remarkably even-handed and very perceptive, seeing both the good and bad in both orthodox and alternative approaches.
Ýòî âåäü íà íàøåì ôîðóìå ïðèíÿòû îäíîçíà÷íûå, êàòåãîðè÷íûå îöåíêè (ðàç è íàâñåãäà) è òîãî ñ ÷åì çíàêîìû è òîãî, ÷òî íå òîëüêî íå èññëåäîâàëè, íî è âîîáùå ñ ÷åì äàæå áëèçêî íå ñòàëêèâàëèñü. Ïðè ýòîì, åñëè âðà÷è íàðÿäó ñ òðàäèöèîííûìè ìåòîäàìè, ïðè èõ íåýôôåêòèâíîñòè äëÿ òÿæåëûõ áîëüíûõ, èñïîëüçóþò è ýòè ñàìûå alternative approaches, òî îíè áåçóñëîâíî îòïåòûå æóëèêè.
  #1479  
Ñòàðûé 21.10.2003, 05:56
E.E. Studentsov E.E. Studentsov âíå ôîðóìà
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 29.06.2003
Ãîðîä: New York, USA
Ñîîáùåíèé: 834
Ñêàçàë(à) ñïàñèáî: 2
Ïîáëàãîäàðèëè 6 ðàç(à) çà 4 ñîîáùåíèé
E.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Âëàäèìèð ßêîâëåâè÷!

Íå ïåðåñòàþ âîcõèùàòüñÿ Âàøèì ïðîçðåíèåì!!! Äåéñòâèòåëüíî, æóëèêè ñ òàêèì æå óñïåõîì ìîãëè âûõâàòèòü èç äàííîé àííîòàöèè âûäåëåííóþ Âàìè öèòàòó: "He is remarkably even-handed and very perceptive, seeing both the good and bad in both orthodox and alternative approaches," è ïðåïîäíåñòè å¸ ÷èòàòåëþ êàê îòíîñÿùóþñÿ ê äîêòîðó Malpas, à íå ê áîëüíîìó ìèåëîìîé ïðåïîäàâàòåëþ îêñôîðäñêîãî óíèâåðñèòåòà Gearin-Tosh. À ìíåíèå ïðîôåññîðà, êîòîðîå îòðàæåíî â ñòàòüå, ñîñòîèò ïî-ìîåìó â òîì, ÷òî áîëüíîé âûæèë âîïðåêè, à íå áëàãîäàðÿ ïðåäëîæåííîé àëüòåðíàòèâíîé òåðàïèè.
Âûðâàííûå èç êîíòåêñòà ôðàçû íå âñåãäà ïåðåäàþò ñìûñë âñåé ñòàòüè. Âî ïåðâûõ, ïî êàêîìó ïîâîäó îíà áûëà íàïèñàíà:
"Journalists seized on it and used it to vilify orthodox medical practice and doctors in general. This was grossly unfair, for Gearin-Tosh does no such thing in his book. "
"So Living Proof of what? Having survived, Gearin-Tosh feels he has the right to draw lessons from his experience. He advocates taking time to consider the opinions offered, and certainly nobody could disagree with that. It would have been right to emphasize that this should be done only after a clinical assessment to rule out such devastating complications as incipient paralysis from spinal cord compression and kidney failure, both of which can develop quickly in classic multiple myeloma. I am sure Gearin-Tosh did not wish to give bad advice to others who have received a diagnosis of multiple myeloma, but the publication of the book and its misinterpretation by the press did prompt the United Kingdom branch of the International Myeloma Foundation, an excellent patient-support organization, to respond with a front-page editorial because so many patients and their families had been upset. "
Íóæíî ó÷åñòü, ÷òî ó àâòîðà êíèãè áûëà stage 1 Multiple Myeloma, è îïÿòü æå, öèòèðóÿ äîêòîðà Malpas "It is not uncommon for an oncologist with a practice in myeloma to see a patient with stage 1 myeloma who survives for many years".  òî âðåìÿ, êîãäà ýòî çàáîëåâàíèå áûëî äèàãíîñòèðîâàíî ó àâòîðà êíèãè, áîëüíûì ñî stage 1 multiple myeloma ïðåäëàãàëèñü äâà âàðèàíòà äàëüíåéøåé òàêòèêè: õèìèîòåðàïèÿ èëè àêòèâíîå íàáëþäåíèå, ïðè êîòîðîì ëå÷åíèå íà÷èíàåòñÿ òîëüêî ïðè âîçíèêíîâåíèè êëèíè÷åñêîé íåîáõîäèìîñòè.  òî âðåìÿ íå áûëî óáåäèòåëüíûõ äàííûõ íàñêîëüêî ïðîãíîç ìåíÿåòñÿ îò ïðåäïî÷òåíèÿ òîãî èëè èíîãî ïîäõîäà. Òàêàÿ ðàáîòà ïîÿâèëàñü ïîçäíåå, î ÷åì è ïèøåò äîêòîð Malpas:"The irony of the whole situation is that a recent randomized trial of treatment for stage 1 multiple myeloma by Riccardi and colleagues (British Journal of Cancer 2000;82:1254-60) showed no advantage of conventional chemotherapy over no treatment.

Òî åñòü åñòü âñå îñíîâàíèÿ ïîëàãàòü, ÷òî íå ïîëó÷àÿ íèêàêîãî ëå÷åíèÿ, Mr.Gearin-Tosh ÷óâñòâîâàë áû ñåáÿ íå õóæå, à ìîæåò áûòü è ëó÷øå, ÷åì ïîëó÷àÿ àãðåññèâíîå àëüòåðíàòèâíîå ëå÷åíèå:
"...such alternative therapies as Gerson therapy with its strict diet, vitamins, and enemas. High-dose vitamin C and high-dose vitamin D, both contraindicated in the orthodox treatment of multiple myeloma..."


Ñïàñèáî, Âëàäèìèð ßêîâëåâè÷, çà Bàøå àêòèâíîå ó÷àñòèå â àíòèøàðëàòàíñêîé äèñêóññèè. Íàéäåííàÿ Âàìè èíôîðìàöèÿ î÷åíü ïîêàçàòåëüíà è óáåäèòåëüíà.

Ñ óâàæåíèåì
Å.Å. Ñòóäåíöîâ
  #1480  
Ñòàðûé 21.10.2003, 12:06
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Óâàæàåìûé Åâãåíèé Åâãåíüåâè÷!

Ôðàçà He is remarkably even-handed and very perceptive, seeing both the good and bad in both orthodox and alternative approaches. Îí â âûñøåé ñòåïåíè áåñïðèñòðàñòåí è î÷åíü ïðîíèöàòåëåí, âèäÿ êàê ïîëüçó òàê è íåäîñòàòêè è â îðòîäîêñàëüíûõ è â àëüòåðíàòèâíûõ ïîäõîäàõ. ÝÒÎ ÊÀÊ ÐÀÇ ÎÖÅÍÊÀ ÄÎÊÒÎÐÀ MALPAS òîãî, ÷òî ïèøåò Gearin-Tosh.

Gearin-Tosh – ïî õàðàêòåðèñòèêå àâòîðà, âûñîêîèíòåëëåêòóàëüíûé è ýðóäèðîâàííûé ïðîô. Îêñôîðäñêîãî óíèâåðñèòåòà, áîëüíîé ìíîæåñòâåííîé ìèåëîìíîé áîëåçíüþ, ïîëó÷èâ íåáëàãîïðèÿòíûé äèàãíîç, âûáðàë äëÿ ñåáÿ àëüòåðíàòèâíîå ëå÷åíèå, âêëþ÷àþùèå â ñåáÿ, â ÷àñòíîñòè, ñòðîãóþ äèåòó, âèòàìèíû, êëèçìû – ò.å. òî ÷òî Âû íàçâàëè ÀÃÐÅÑÑÈÂÍÎÅ àëüòåðíàòèâíîå ëå÷åíèå ( â îòëè÷èå, ïî-âèäèìîìó, îò ìèëîé, ìÿãêîé, íå àãðåññèâíîé õèìèîòåðàïèè). È íà óäèâëåíèå âåäóùèõ îíêîëîãîâ Àíãëèè è ÑØÀ îñòàëñÿ æèâ, ò.ê. áîëüíûå ñ òàêèì äèàãíîç ïî èõ ïðàêòèêå, òàê äîëãî íå æèâóò.

Òåïåðü î Âàøåì ïðåäïîëîæåíèÿõ, ÷òî äåñêàòü: «ïî ìíåíèþ ïðîôåññîðà, êîòîðîå îòðàæåíî â ñòàòüå, ñîñòîèò ïî-ìîåìó â òîì, ÷òî áîëüíîé âûæèë âîïðåêè, à íå áëàãîäàðÿ ïðåäëîæåííîé àëüòåðíàòèâíîé òåðàïèè». «Òî åñòü âñå îñíîâàíèÿ ïîëàãàòü, ÷òî íå ïîëó÷àÿ íèêàêîãî ëå÷åíèÿ, Mr.Gearin-Tosh ÷óâñòâîâàë áû ñåáÿ íå õóæå, à ìîæåò áûòü è ëó÷øå, ÷åì ïîëó÷àÿ àãðåññèâíîå àëüòåðíàòèâíîå ëå÷åíèå»
Ïðèâåäÿ â êà÷åñòâå äîêàçàòåëüñòâà ôðàçó: "...such alternative therapies as Gerson therapy with its strict diet, vitamins, and enemas. High-dose vitamin C and high-dose vitamin D, both contraindicated in the orthodox treatment of multiple myeloma..." îáðûâàåòå å¸ â òàì, ãäå Âàì ïîêàçàëîñü âûãîäíî.
À âåäü äàëåå áûëî: What is evident is that this was the right therapy for him. Òî, ÷òî ÿâëÿåòñÿ î÷åâèäíûì, - ÷òî ýòî áûëî ïðàâèëüíîé òåðàïèåé äëÿ íåãî.
Åâãåíèé Åâãåíüåâè÷, à âåäü âðà÷è, êîòîðûõ Âû íàçûâàåòå æóëèêàìè, òàêèìè ïðèåìàìè íå ïîëüçîâàëèñü.

Òàê ÷òî, Åâãåíèé Åâãåíüåâè÷, ÿ ñ Âàìè ñîëèäàðåí: ýòà äèñêóññèÿ î÷åíü ïîêàçàòåëüíà êàêèì îáðàçîì îïðåäåëåííûå ãðóïïû âðà÷åé àãðåññèâíî âäàëáëèâàþò â ñîçíàíèå êîëëåã è áîëüíûõ, ÷òî èìåííî è òîëüêî èõ ïðàêòèêà ÿâëÿåòñÿ åäèíñòâåííî ïðàâèëüíîé.
  #1481  
Ñòàðûé 21.10.2003, 21:08
Àâàòàð äëÿ yananshs
yananshs yananshs âíå ôîðóìà Ïîë æåíñêèé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.02.2003
Ãîðîä: NY
Ñîîáùåíèé: 9,664
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 56 ðàç(à) çà 51 ñîîáùåíèé
yananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåyananshs ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Øàðëàòàíñòâî â ìåäèöèíå, îêàçûâàåòñÿ, íå î÷åíü èçìåíèëîñü ñî âðåìåí À.Ï.×åõîâà. Âîò îòðûâîê èç âîñïîìèíàíèé Àë.Ï.×åõîâà î äåòñêèõ ãîäàõ Àíòîíà Ïàâëîâè÷à:

"Íàçíà÷åíèå ìíîãèõ òîâàðîâ áûëî äëÿ Àíòîøè-ãèìíàçèñòà äîëãîå âðåìÿ çàãàäêîþ.
- Ïàïàøà, äëÿ ÷åãî ïðîäàåòñÿ ñåìèáðàòíÿÿ êðîâü? - ñïðàøèâàë îí ó îòöà.
- Îò ëèõîðàäêè.
- À ãíåçäî?
- Êîãäà âûðàñòåøü, òîãäà è óçíàåøü...
Ñåìèáðàòíÿÿ êðîâü - ýòî èçâåñòêîâûé ñêåëåò ïðèâîçèìîãî èç-çà ãðàíèöû êîðàëëà. Ýòî - òðóá÷àòûé êàìåíü òåìíî-ìàëèíîâîãî öâåòà, ñîâåðøåííî íåðàñòâîðèìûé â âîäå. Îò òàêîãî ëåêàðñòâà âñÿêèé äîêòîð ïðèøåë áû â óæàñ. Íî îáûâàòåëè òîëêëè åãî â ïîðîøîê, ïèëè ñ âîäêîþ âî âðåìÿ ëèõîðàäêè è... ñëàâà áîãó, îñòàâàëèñü æèâû. À ïðåñëîâóòîå "ãíåçäî" òàê è îñòàëîñü äëÿ Àíòîíà Ïàâëîâè÷à íåðàçãàäàííûì äàæå è òîãäà, êîãäà îí óæå ñàì áûë âðà÷îì.  ñîñòàâ ýòîãî óäèâèòåëüíîãî ëåêàðñòâà âõîäèëî ìíîãîå ìíîæåñòâî êàêèõ-òî òðàâ, ïîðîøêîâ è ìèíåðàëîâ. Àíòîí Ïàâëîâè÷ óæå â çðåëûå ãîäû ïðîáîâàë çàïèñàòü ïî ïàìÿòè ñîñòàâ ýòîãî "ãíåçäà" è âñïîìíèë, ìåæäó ïðî÷èì, ÷òî òóäà âõîäèëè: íåôòü, ìåòàëëè÷åñêàÿ ðòóòü (æèâîå ñåðåáðî), àçîòíàÿ êèñëîòà (îñòðàÿ âîäêà), ñåìèáðàòíÿÿ êðîâü, ñòðèõíèí (êó÷åëàáà), ñóëåìà, êàêîé-òî äåêîêò â âèäå äëèííûõ ñåðûõ ïàëî÷åê è öåëàÿ óéìà âñÿêîé äðÿíè. Âñå ýòî íàñòàèâàëîñü íà âîäêå è äàâàëîñü âíóòðü ñòîëîâûìè ëîæêàìè. Óïîòðåáëåíèå ýòîãî ëåêàðñòâà Àíòîøà óçíàë ñëó÷àéíî ðàíüøå òîãî âðåìåíè, êîòîðîå Ïàâåë Åãîðîâè÷ îïðåäåëèë ñëîâàìè: "Êîãäà âûðàñòåøü, òîãäà è óçíàåøü". Âîøåë îäíàæäû â ëàâêó õîõîë è ïîòðåáîâàë ó Ïàâëà Åãîðîâè÷à "÷åòâåðòü ãíåçäà". Àíòîøà áûë òóò æå.
- Äëÿ êàêîé âàì íàäîáíîñòè? - îñâåäîìèëñÿ Ïàâåë Åãîðîâè÷.
- Æèíêà ðîäèëà, è òåïåðü ó íåå â æèâîòå óæå òðåòèé ìåñÿö çîëîòíèê õîäèò, - îòâåòèë õîõîë.
Àíòîøà òîò÷àñ æå âîîáðàçèë, ÷òî õîõëóøêà, î êîòîðîé øëà ðå÷ü, âåðîÿòíî íå÷àÿííî ïðîãëîòèëà òîò ñàìûé ìåäíûé çîëîòíèê, êîòîðûé êëàäåòñÿ íà âåñû, êîãäà îòâåøèâàåòñÿ íà äâå êîïåéêè ÷àþ. Íî äëÿ Ïàâëà Åãîðîâè÷à ýòîãî äèàãíîçà áûëî ñîâåðøåííî äîñòàòî÷íî, è îí íåìåäëåííî ïðèíÿëñÿ çà ïðèãîòîâëåíèå ëåêàðñòâà.
- À áóäåò "ãíåçäî" äåéñòâîâàòü? - óñîìíèëñÿ õîõîë.
- Íåïðåìåííî ïîäåéñòâóåò, - óâåðåííî îòâåòèë Ïàâåë Åãîðîâè÷. - Ñàì âèäèøü, òóò ðàçíûå ñïåöèè: îäíî ïîòÿíåò ñþäà, äðóãîå - òóäà; çîëîòíèê è ïåðåñòàíåò õîäèòü ïî æèâîòó. Õîõîë óäîâëåòâîðèëñÿ âïîëíå ýòèì îòâåòîì, óïëàòèë äåíüãè è óøåë ñîâåðøåííî äîâîëüíûé. Íî Àíòîí Ïàâëîâè÷ ïîòîì, óæå èçó÷àÿ â óíèâåðñèòåòå õèìèþ, íèêàê íå ìîã äîäóìàòüñÿ äî òîãî, êàêóþ ïîëüçó ìîãëà ïðèíåñòè ðîæåíèöå ìåòàëëè÷åñêàÿ ðòóòü, ïðèíÿòàÿ âíóòðü â ñìåñè ñ íåôòüþ è àçîòíîé êèñëîòîé.
- Ìíîãî, âåðîÿòíî, îòïðàâèëî íà òîò ñâåò ëþäåé ýòî "ãíåçäî", - ãîâàðèâàë îí, óæå áóäó÷è âðà÷îì.
À ìåæäó òåì â äíè äåòñòâà îí îòâåøèâàë ðàçíûå ñíàäîáüÿ äëÿ ýòîãî ëåêàðñòâà ñ òàêîþ ñïîêîéíîþ ñîâåñòüþ, ñ êàêîþ îòâåøèâàë êîôå èëè îòìåðèâàë êîíîïëÿíîå ìàñëî...
Äîëãî ïîìíèë Àíòîí Ïàâëîâè÷ è êàêîé-òî "ñîðîêàòðàâíèê", ïðîäàâàâøèéñÿ â ïàêåòàõ, çàâåðíóòûõ â âûöâåòøóþ çîëîòóþ è ñåðåáðÿíóþ áóìàãó. ×òî ýòî áûëè çà òðàâû - òàê è îñòàëîñü íåèçâåñòíûì; èçâåñòíî áûëî òîëüêî îäíî, ÷òî âîäî÷íûé íàñòîé èõ ðåêîìåíäîâàëñÿ áóêâàëüíî îò âñåõ áîëåçíåé, îñîáåííî æå ïðè ãîðÿ÷êå. Ïîìíèë Àíòîí Ïàâëîâè÷ òàêæå è "âñåèñöåëÿþùèé ïëàñòûðü äîêòîðà Àëÿêðèíñêîãî", ïðîäàâàâøèéñÿ â êðóãëûõ êàðòîííûõ êîðîáî÷êàõ. Ñ ýòèì ïëàñòûðåì, ìåæäó ïðî÷èì, íà ãëàçàõ ó Àíòîøè áûë ïðîèçâåäåí ýêñïåðèìåíò. Ïî Òàãàíðîãó õîäèë è íèùåíñòâîâàë äóðà÷îê Êëèìêà. Çàøåë îí çà ìèëîñòûíåé è â ëàâêó ê Ïàâëó Åãîðîâè÷ó êàê ðàç â òî âðåìÿ, êîãäà êîìïàíèÿ ïðàçäíûõ ìàêëåðîâ-çàâñåãäàòàåâ áûëà óæå ïîðÿäî÷íî íà âçâîäå. Îò íå÷åãî äåëàòü ýòà ìèëàÿ êîìïàíèÿ ïðåäëîæèëà Êëèìêå ñòàêàí âîäêè è ïÿòàê ïîä óñëîâèåì, ÷òî îí çàêóñèò âûïèâêó ïëàñòûðåì Àëÿêðèíñêîãî. Äóðà÷îê ñîãëàñèëñÿ è ñúåë öåëóþ êîðîáî÷êó. Ïîñëå ýòîãî åãî åùå ìíîãî ëåò âèäåëè íà ïîõîðîííûõ è ñâàäåáíûõ ïðîöåññèÿõ çäðàâûì è íåâðåäèìûì...
Íåñìîòðÿ, îäíàêî æå, íà òàêîé óäà÷íûé èñõîä, ïëàñòûðü ýòîò íàõîäèë ñåáå ìàëî ïîêóïàòåëåé. Îäíó êîðîáêó åãî âçÿë ïîëèöåéñêèé ÷èíîâíèê äëÿ ñâîåé îïàðøèâåâøåé îõîòíè÷üåé ñîáàêè, íî äåíåã íå çàïëàòèë, à Ïàâåë Åãîðîâè÷ íàïîìíèòü åìó î äîëãå íå ðåøàëñÿ è òîëüêî îäíàæäû, ïðè âñòðå÷å íà áàçàðå çàèñêèâàþùèì òîíîì ñïðîñèë:
- ×òî, êàê ñîáà÷êà âàøà? Ïîïðàâèëàñü îò ïëàñòûðÿ?
- Èçäîõëà, - îòâåòèë óãðþìî ïîëèöåéñêèé. - Ó íåå â æèâîòå çàâåëèñü ÷åðâè..."
  #1482  
Ñòàðûé 30.10.2003, 19:41
Ãîñòü (62.213.7.150)
Ãîñòü
 
Ñîîáùåíèé: n/a
Ñåìèáðàòíÿÿ êðîâü - ýòî Ñorrallium rubrum. Äåéñòâèå åãî ãîìåîïàòè÷åñêîå. Âåëèêîëåïíûé ïðåïàðàò ïðè êîêëþøå è ëåãî÷íîì òóáåðêóë¸çå! Åñëè áû Àíòîí Ïàâëîâè÷ âìåñòî, ÷òîá ¸ðíè÷àòü, âíèìàòåëüíî èçó÷èë åãî ñâîéñòâà, òî, ãëÿäèøü, íå ñêîí÷àëñÿ áû â 43 îò "òÿæåëîé è ïðîäîëæèòåëüíîé"...

[img=http://panacea.narod.ru/Rus/Other/img_0719.gif][/img]
  #1483  
Ñòàðûé 06.11.2003, 07:11
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
"Ñåìèáðàòíÿÿ êðîâü" èëè ãîìåîïàòîâ ê îòâåòó!

Æåíùèíà Ñ. 47 ëåò, ëåòîì 2002 ã. îáðàòèëàñü â ÑÏá ÍÈÈ îíêîëîãèè èì. Ïåòðîâà. Ïðè îáñëåäîâàíèè ðàê øåéêè ìàòêè ñ èíâàçèåé â çàäíþþ ñòåíêó ìî÷åâîãî ïóçûðÿ (Ò3bN1M0) óæå òîãäà íå îïåðàáåëüíûé. Äî ýòîãî "ëå÷èëàñü" ó ãîìåîïàòîâ 7 ìåñÿöåâ. Ïîëó÷èëà ëó÷åâóþ òåðàïèþ, â òå÷åíèå 1 ãîäà ðîñò îïóõîëè çàìåäëèëñÿ. Îäíàêî â í.â. - ïðîãðåññèðîâàíèå çàáîëåâàíèÿ, êîìïðåññèÿ óñòüåâ ìî÷åòî÷íèêîâ, äâóõñòîðîííèé ãèäðîíåôðîç...

Êàêîå ïðàâî ýòè ìåðçàâöû (äðóãîãî ñëîâà íå íàõîæó), íå âûëå÷èâøèå â ðåàëüíîñòè íè îäíîãî îíêîáîëüíîãî (îíè íå ìîãóò ïîñòàâèòü íè îíêîäèàãíîç, íè îïðåäåëèòü ñòàäèþ çàáîëåâàíèÿ êðîìå ýòîãî) áåðóòñÿ çà òàêèõ òÿæåëûõ áîëüíûõ??? Íó ëàäíî òàì "ëå÷èòå" âû íàñìîðê, ìèãðåíü, áðîíõèàëüíóþ àñòìó è ò.ï. çàáîëåâàíèÿ, êîòîðûå ÷àñòî è áåç ëå÷åíèÿ ïðîõîäÿò/âõîäÿò â ðåìèññèþ. Íî îíêîáîëüíûå!!!??? Ýòî íàäî áûòü èëè àáñîëþòíî ñóìàñøåäøèì èëè áåññîâåñòíûì, ÷òîáû çàÿâëÿòü îá ýôôåêòèâíîñòè ãîìåîïàòèè ïðè îíêîïàòîëîãèè. Íó à êîãäà ãîìåîïàò ïîëüçóåò îíêîáîëüíóþ äëèòåëüíîå âðåìÿ, à ðàê ïåðåõîäèò â íåèçëå÷èìóþ/íåîïåðàáåëüíóþ ñòàäèþ, îí (ãîìåîïàò) ñòàíîâèòñÿ óáèéöåé. Âîò òàêèå ïðèìåðû èç ïðàêòèêè.
  #1484  
Ñòàðûé 06.11.2003, 17:34
Ãîñòü (148.209.3.5)
Ãîñòü
 
Ñîîáùåíèé: n/a
Íó, íàø ñòàðèíà Æèâîâ ïîåõàë óæå îêîí÷àòåëüíî. Íå óìåÿ íè÷åãî, êðîìå êàê òðåïàòüñÿ â Èíòåðíåòå î ñîáñòâåííûõ ïîåçäêàõ â ÑØÀ è òðàâèòü ê ìåñòó è íå ê ìåñòó áîëüíûõ àíòèáèîòèêàìè, îí òåïåðü íà ãîìåîïàòîâ ðåøèë íàëåòåòü, òåì áîëåå ÷òî âñå ãîìåîïàòû äàâíî óæå íà ÐÌÑ ïîëîæèëè è îòâåòèòü íåêîìó. "Áðàâî, íÿíÿ!". Âïåðåä, çàäîðíûé Ëåøà. Òû âåäü èçâåñòíûé ñïåö â ëå÷åíèè îíêîáîëüíûõ, îíè ó òåáÿ âñå êàê îäèí âûçäîðàâëèâàþò, íå ÷åòà ãîìåîïàòàì. "Ëå÷èòå ðàê ó Æèâîâà - áóäåòå æèâû!". À ÷òî, çâó÷èò.
  #1485  
Ñòàðûé 06.11.2003, 18:56
Àâàòàð äëÿ Vladlen
Vladlen Vladlen âíå ôîðóìà
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.05.2003
Ãîðîä: Israel
Ñîîáùåíèé: 413
Vladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
The treatment of cervical cancer varies with the stage of the disease. For early invasive cancer, surgery is the treatment of choice. In more advanced cases, radiation combined with chemotherapy is the current standard of care. In patients with disseminated disease, chemotherapy or radiation provides symptom palliation.

Prognosis:

Prognosis of cervical cancer depends on disease stage. In general, the 5-year survival rate for stage I disease is higher than 90%, for stage II is 60-80%, for stage III is approximately 50%, and for stage IV disease is less than 30%.
Çàêðûòàÿ òåìà



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 10:13.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.